BPC-157 and TB-500 head to FDA review in July 2026

What the FDA is reviewing and when

The Pharmacy Compounding Advisory Committee meets twice in late July. Day one covers four peptides: BPC-157, TB-500, KPV, and MOTs-C. Day two covers three more: emideltide (also called delta sleeping inducing peptide, or DSIP), Semax, and Epitalon. Each is being considered as a bulk drug substance under the 503A compounding framework.

The meeting runs at the FDA White Oak Campus in Silver Spring, Maryland. Virtual attendance is available. Nominators of each substance will present supporting evidence. A public comment session is included.

The public docket is FDA-2025-N-6895. Comments go to regulations.gov. If the number of people who register to speak in-person exceeds available time, the FDA will run a lottery.

Why this is different from April's reclassification

In April 2026, the FDA removed BPC-157, TB-500, and several other peptides from Category 2 of the 503A restrictions. Category 2 flagged substances with unresolved safety or efficacy concerns that restricted compounders from using them. Removal from that category lowered a barrier. It did not create a formal green light.

The 503A Bulk Drug Substances List is different. A substance on that list has the FDA's affirmative recognition that it can be used in individualized compounded prescriptions. It is not FDA approval of BPC-157 as a drug. BPC-157 would still have no approved clinical indication. But a physician could prescribe it, and a licensed 503A pharmacy could compound it, with quality standards applied.

That distinction matters practically. Right now, a compounder working with BPC-157 is operating in a space with reduced restrictions but no formal authorization. A Bulks List entry would close that gap.

What the committee actually weighs

The PCAC reviews four factors for each nomination. Physical and chemical characterization: can the substance be consistently identified, purified, and formulated? Safety for compounded use: are there risks specific to how it would be prepared and administered? Evidence of effectiveness: what does the literature show? And historical use in compounding: has this substance been prescribed through pharmacies before?

For BPC-157, the four-factor breakdown looks like this. Chemical characterization is straightforward: the peptide sequence is well-defined and synthesis methods are established. Historical compounding use is substantial: BPC-157 has circulated through the compounding ecosystem for years. The safety record from that use is generally clean, though uncontrolled and self-reported.

The effectiveness criterion is where the committee faces a real question. Animal data for BPC-157 is extensive and shows real effects: faster tendon and ligament repair, gut tissue recovery, anti-inflammatory action, new blood vessel formation. The problem is the human literature. There are three published human studies. None used a proper control group. That is not nothing, but it is far from what would normally support an affirmative recommendation.

BPC-157's evidence profile

The BPC-157 research base sits at an unusual intersection. The mechanism is plausible and well-characterized. The animal data is unusually consistent across dozens of studies. There is essentially no credible evidence of serious harm in the compounding literature. And yet there are only three published human studies, all small, all lacking control groups.

A scoping review published in December 2025 noted that all published BPC-157 studies report positive effects, which itself raises questions about publication bias. Negative or null results may exist but not be in the literature. The committee will consider this.

The political context

This hearing is not happening in a regulatory vacuum. The current administration has been openly skeptical of FDA restrictions on peptides and supplements. The April 2026 reclassification was a direct product of that posture. The July hearing is the formal mechanism for the next step.

RFK Jr. at HHS and DOGE-driven FDA reform both signal a preference for reducing restrictions on compounds with plausible mechanisms and existing community use, even where formal clinical trials are limited. The biopharmaceutical industry has also eased restrictions in this direction.

You can read the regulatory trajectory two ways. Either the FDA had been excessively conservative on compounds that have been widely used with a reasonable safety record, and the hearing corrects that balance. Or the clinical evidence bar is being lowered before the human data is in. Both readings have some support. What is not in dispute is that the July hearing represents the most significant formal regulatory moment for these peptides since their initial reclassification.

TB-500, KPV, MOTs-C and the other peptides on the list

BPC-157 tends to dominate coverage of this hearing, but six other peptides are on the same docket.

TB-500, the thymosin beta-4 fragment, shares a similar profile: strong animal data, particularly from equine medicine where it has been used for decades, thin human clinical literature. KPV is a tripeptide studied for inflammatory bowel disease with promising preclinical data. MOTs-C is a mitochondria-derived peptide with early research suggesting metabolic effects.

Semax is a neuropeptide developed in Russia with cognitive and neuroprotective properties studied in small Eastern European trials. Epitalon is a tetrapeptide studied for telomere effects, largely in animal and small human studies. DSIP (delta sleeping inducing peptide, listed here as emideltide) has been researched for sleep regulation since the 1970s.

Each faces the same committee process. The ones with more human data will have an easier case. BPC-157 and TB-500 are the most widely used in the compounding ecosystem, which helps the historical use criterion even where clinical trial data is sparse.

What to watch after the hearing

The committee issues recommendations, not binding decisions. The FDA reviews the recommendation and makes the final call on what gets added to the Bulks List. There is no set timeline for the FDA to respond.

If the committee recommends inclusion for BPC-157 and TB-500 and the FDA follows through, the access picture changes in a specific and meaningful way. A physician can write a prescription. A licensed 503A pharmacy can compound the peptide under USP 797 sterile preparation standards, with a Certificate of Analysis confirming purity. That is a different product from what a research chemical vendor ships.

The gray market does not go away. Research chemical sites operate outside this framework. A positive outcome from July 23 only affects the compounding pharmacy channel. But for people who want physician oversight and quality-controlled product, it would create something that does not quite exist today.

For more on what was already covered by the April change and what to look for in a legitimate compounder, see the April 2026 reclassification breakdown. For the evidence on stacking these peptides with a GLP-1, see BPC-157 with a GLP-1. And for the broader peptide landscape and what is showing the most evidence, the peptide stacks guide covers the current field.